Problems of Glioblastoma Multiforme Drug Resistance

Area of Science:

• Neuro-oncology
• Molecular Biology
• Cancer Genetics

Background:

• Glioblastoma multiforme (GBL) is the most aggressive primary brain tumor.
• Standard treatment involves surgery, radiation, and temozolomide (TMZ) chemotherapy.
• Current therapies yield a median survival of only 14.6 months, highlighting treatment limitations.

Purpose of the Study:

• To review the molecular mechanisms of GBL resistance to TMZ.
• To discuss genetic and epigenetic factors contributing to TMZ resistance.
• To identify potential therapeutic targets for overcoming GBL treatment resistance.

Main Methods:

• Literature review of molecular mechanisms in GBL resistance.
• Analysis of genetic factors including MGMT, IDH1/2, YB-1, MELK, MVP/LRP, MDR1 (ABCB1), and Akt3.
• Review of epigenetic regulators such as microRNA and EZH2.

Main Results:

• Multiple genes and proteins (MGMT, IDH1/2, YB-1, MELK, MVP/LRP, MDR1, Akt3) are implicated in GBL TMZ resistance.
• Epigenetic factors, including microRNA and EZH2, also play a significant role.
• These molecular alterations contribute to the limited efficacy of standard GBL treatment.

Conclusions:

• GBL resistance to TMZ is multifactorial, involving both genetic and epigenetic pathways.
• Targeting these specific molecular mechanisms may offer novel therapeutic strategies.
• Further research into these resistance pathways is crucial for improving GBL patient outcomes.